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ABSTRACT
Wereport a crystal structure that shows an antibiotic
that extracts a nucleobase from a DNA molecule
‘caught in the act’ after forming a covalent bond but
before departing with the base. The structure of
trioxacarcin A covalently bound to double-stranded
d(AACCGGTT) was determined to 1.78A ˚ resolution
by MAD phasing employing brominated oligonucleo-
tides. The DNA–drug complex has a unique structure
that combines alkylation (at the N7 position of a
guanine), intercalation (on the 3’-side of the alkylated
guanine), and base flip-out. An antibiotic-induced
flipping-out of a single, nonterminal nucleobase
from a DNA duplex was observed for the first time
in a crystal structure.
INTRODUCTION
Trioxacarcins were ﬁrst isolated in 1981 from the marine-
derived micro-organism Streptomyces bottropensis DO-45
(1,2). They are cytotoxic against various cancer cell lines,
active against Gram-positive and Gram-negative bacteria
and exhibit anti-malarial activity (3). Trioxacarcin A
(Figure 1) contains a complex ring system that is attached
to sugars at both ends, at the 4- and 13-positions, and
causes it to exhibit intensive green ﬂuorescence in solution;
in powder form it is yellow. Nucleophilic attack of N7
of guanine opens the ‘epoxide (1)’ to form a covalent
bond to the ‘guanine (2)’ in a DNA molecule (Figure 2).
This alkylation is favored when a thymine is located
on the 30-side of guanine and does not take place when
the guanine is terminal (4). Cleavage of this trioxacarcin–
‘DNA (3)’ complex at 373K results in the natural product
‘gutingimycin (4)’ (3,5), named after the ancient name for
the city of Go ¨ ttingen, leaving an abasic DNA. Presumably,
this cleavage takes place under milder conditions in vivo.
Anthracyclines resemble trioxacarcin A in that they also
contain a planar aromatic ring system with one or more
sugars attached to it, although they can only intercalate
but not bind covalently to DNA. Some of them are used
for the treatment of various cancer types, e.g. daunomycin
(=daunorubicin) against leukemia. In DNA–daunomycin
complexes, the positively charged amino sugar of dauno-
mycin is positioned in the minor groove of DNA (6). The
anthracycline nogalamycin has bulky sugar residues at
both ends of the molecule that interact with both grooves
of DNA (7). Pluramycin antibiotics (8) such as hedamycin
(9) and altromycin B (10), and also psorospermin (11),
are even more similar to trioxacarcin A because they
contain in addition one or more epoxides and so can both
intercalate and alkylate DNA; like trioxacarcin they
bind covalently to the guanine N7. However, no crystal
structures have been reported of such covalent antibiotic–
DNA complexes.
To throw more light onto the stereochemical require-
ments for the covalent bond formation and subsequent
elimination of a nucleobase, we have determined the
structure of trioxacarin A covalently bound to an oligo-
nucleotide to 1.78A ˚ resolution by X-ray diﬀraction.
Experimental phases were obtained by MAD experi-
ments using isomorphous crystals containing brominated
nucleotides. The crystal structure reveals an unexpected
base ﬂip-out at the intercalation site.
MATERIALS AND METHODS
Trioxacarcin A was obtained from the marine
Streptomyces sp. isolate B8652 by fermentation (12).
Oligonucleotides were purchased already puriﬁed by
HPLC from biomers.net GmbH and used without further
puriﬁcation. Crystals were grown at 408C in hanging
drops by vapor diﬀusion; we found by experiment that the
higher than usual temperature produced better quality
single crystals. The solution in the reservoir contained
1.55M tri-ammonium citrate (pH 7.0) and 30% v/v
DMSO. The DNA–drug solution contained 2.5mM
DNA (single-strand concentration), 2.8mM trioxacarcin
A and 25% v/v methanol. The DNA–drug solution was
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taining 5.0mM trioxacarcin A and 50% v/v methanol)
with a 5.6mM DNA solution in a 1:1 ratio at room
temperature and incubation for 3 days at 48C. The
hanging drops prepared from 1ml DNA-drug solution
and 2ml reservoir solution were equilibrated against 500ml
reservoir solution. Yellow tetragonal crystals grew within
24h to a size of 0.2   0.1   0.05mm. For data collection
at 100K in a nitrogen gas stream, the crystals were trans-
ferred to a cryosolution containing 1.55M tri-ammonium
citrate (pH 7.0), 30% v/v DMSO and 15% v/v glycerol.
Three diﬀerent oligonucleotides were used to obtain
crystals as described above: native d(AACCGGTT) and
brominated d(AACCGG
5BrUT) and d(AACCGGT
5BrU).
In the brominated oligonucleotides thymidine is replaced
by 5-bromodeoxyuridine.
The DNA–drug complex crystallized in space group
P4122 with unit-cell a=b=37.60A ˚ and c=91.62A ˚ .
Data were collected at beamline 14.2 at BESSY,
Berlin with a MAR-165 CCD detector. The crystals con-
taining brominated oligonucleotides were used for two
Br-MAD experiments. From both crystals, peak and
inﬂection datasets were collected, 180 frames for each
dataset with a u-rotation of 18 per frame (see Table 1 for
crystallographic details). In order to avoid radiation
damage, an 0.53mm aluminium ﬁlter was used to decrease
the intensity of the direct beam. In addition, a native
dataset was collected to 1.78A ˚ resolution from a crystal
containing the native oligonucleotide.
The datasets were integrated with HKL2000 (13) and
the space group determined by XPREP (Bruker AXS,
Madison WI, USA). SHELXD (14) was used for sub-
structure solution by searching for two bromine atoms
with a resolution cutoﬀ at 2.6A ˚ . Substructure solution
succeeded only with the d(AACCGG
5BrUT)-derivative,
probably because the crystals diﬀracted better. SHELXE
(15) was employed for phasing and density modiﬁcation.
In the experimental map, the position of thymine could be
deduced from the bromine positions from the substructure
solution and the anomalous maps calculated using
SHELXE. It was also possible to recognize the drug in
the experimental map (Figure 3A). The asymmetric unit
consists of one complete duplex with two intercalated
trioxacarcins. The graphics program COOT (16) was used
for model building. The structure was reﬁned isotropically
with TLS constraints against the native dataset with
REFMAC (17) to Rwork=22.0% and Rfree=26.5%
(Figure 3B). Helical parameters were calculated with
3DNA (18). Figures 3 and 5–7 were generated using
PYMOL (DeLano Scientiﬁc LLC, South San Francisco
CA, USA).
RESULTS AND DISCUSSION
Overall structure
As predicted in the study of the sequence speciﬁcity (4),
trioxacarcin A binds covalently to d(AACCGGTT) by
alkylating the N7 position of the guanine that is followed
by a thymine. Unexpectedly, this thymine is ﬂipped out of
the duplex DNA and the adenine originally paired with it
now forms a base pair with the following thymine in the
sequence. Trioaxacarcin A intercalates at the 30-side of the
alkylated guanine (Figure 4). The aromatic rings A and B
of the drug are involved in stacking interactions with the
DNA. As found for nogalamycin (7), trioxacarcin A
interacts with both grooves of the DNA (Figure 5); the
4-sugar is positioned in the minor groove, the 13-sugar in
the major groove.
Figure 2. Proposed mechanism for the reaction of trioxacarcin A with DNA. Only the epoxide group of trioxacarcin A (1) is shown, the rest of the
molecule is described by R1 and R2. R3 stands for the abasic DNA.
Figure 1. Schematic diagram of trioxacarcin A.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3509Since the duplex does not lie on a 2-fold axis, the two
self-complementary strands are crystallographically inde-
pendent, with some small structural diﬀerences caused
by interactions of the residues A(1), A(101), T(7) and
T(107), which are no longer base-paired within the duplex,
with diﬀerent symmetry related residues in the crystal.
A(1) forms a Hoogsteen base pair with a symmetry
equivalent of T(7). In contrast, T(107) lies close to a
symmetry equivalent of itself. Residue A(101) does not
appear to make speciﬁc contacts to neighboring molecules
and is highly disordered, whereas N1 of A(1) accepts an
hydrogen bond (2.7A ˚ ) from a symmetry equivalent of
Table 1. Data collection, phasing and reﬁnement statistics
Native d(AACCGG
5BrUT) d(AACCGGT
5BrU)
Crystal data
Space group P4122 P4122 P4122
a, A ˚ 37.60 37.60 37.56
c, A ˚ 91.62 91.21 90.97
Peak inﬂection peak inﬂection
Diﬀraction data
Wavelength, A ˚ 0.92039 0.92032 0.92047 0.92033 0.92042
Resolution limit, A ˚ 1.67 2.18 2.18 2.39 2.39
Total reﬂections 103552 45885 46392 36333 29272
Unique reﬂections 8225 3789 3790 2917 2756
Completeness, %
Overall 99.0 89.7 98.7 98.8 93.4
Outermost resolution shell 94.7 89.3 98.5 90.7 59.4
I/(I)
Overall 27.81 13.2 14.6 13.8 14.8
Outermost resolution shell 2.92 4.5 4.2 2.7 1.5
Phasing
Resolution, A ˚ 2.6
Pseudo-free CC after dm 0.61
Reﬁnement
Reﬂections used 6488
Resolution, A ˚ 1.78
Rwork 22.0
Rfree 26.5
rms deviation
Bond length, A ˚ 0.016
Bond angles, 8 2.5
Average B factor (all atoms), A ˚ 2 53.16
Figure 3. Experimental map (A) and map after ﬁnal reﬁnement (B), both contoured at a 1s level. The carbon atoms of the trioxacarcin are shown in
light orange.
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of both strands are fairly similar except for residues A(1)
and A(101) that are positioned at the 50-terminus of the
oligonucleotide and do not base pair within the duplex.
The DNA–trioxacarcin duplex shows a distorted B-DNA
geometry with Watson–Crick base pairing. In Table 2, the
sugar-phosphate and glycosyl torsion angles are compared
with the usual ranges and mean values for B-DNA (19).
The ﬂipping-out of T(7) is most evident in its z torsion
angle of 828 [748 for T(107)] that diﬀers by about 1808
from the standard value. The other torsion angles all lie in
ranges typically observed in B-DNA structures.
Antibiotic–DNA interactions
In addition to the covalent bond, trioxacarcin A forms
direct and water mediated hydrogen bonds with the DNA
(Figure 6). There is an hydrogen bond between the 2-OH
of trioxacarcin and O40 of the deoxyribose attached to
the cytosine opposite to the alkylated guanine [2.8A ˚
for trioxacarcin(9) and 2.7A ˚ for trioxacarcin(109)]. In the
minor groove, N2 of the alkylated guanine donates an
hydrogen bond to 30-OH of the 4-sugar of trioxacarcin
(3.1A ˚ for both trioxacarcins). There is also a water-
mediated hydrogen bond between N3 of the alkylated
guanine and 30-OH. The 4-sugar interacts only with the
alkylated guanine. In the major groove, the 100-oxygen of
the 13-sugar of trioxacarcin(109) accepts an hydrogen
bond (3.2A ˚ ) from N6 of residue A(2). In the case of
trioxacarcin(9) and A(102), the corresponding hydrogen
bond is mediated by a water molecule, giving rise to a small
diﬀerence between the two strands. The 13-sugar is also
involved in an internal hydrogen bond [3.4A ˚ for triox-
acarcin(9) and 3.1A ˚ for trioxacarcin(109)] between 300-OH
and 14-OH (Figure 6), stabilizing the OH-group formed by
the nucleophilic attack on the epoxide ring. The 13-sugar
of the trioxacarcin is held parallel to the trioxacarcin
chromophore by this internal hydrogen bond, whereas the
4-sugar is orientated perpendicular to it.
For the formation of gutingimycin, the guanine–sugar
bond between N9 and C10 (Figure 7A) has to break and
the antibiotic has to leave the DNA duplex taking the
guanine with it. Assuming that the guanine–sugar bond
breaks whilst the double strand is still intact, gutingimycin
would then only be attached to the abasic DNA by two
hydrogen bonds because one hydrogen bond involved
a symmetry equivalent that would not be relevant in
solution and the other two hydrogen bonds that held it in
place are between the 4-sugar of the trioxacarcin and the
guanine. After leaving, the guanine rotates by about 1808
to give the conformation observed in the crystal structure
of gutingimycin (5) that is stabilized by stacking interac-
tions between the guanine and the chromophore; this
would inhibit re-intercalation of the gutingimycin into the
DNA. Figure 7B shows the crystal structure of gutingi-
mycin (5) in a similar orientation to the bound triox-
acarcin in the DNA–drug duplex (Figure 7A), illustrating
the 1808 rotation of the guanine base. N2 of this guanine
lies above ring C in both structures. In the DNA–drug
complex, N3 is positioned above ring B and N9 above
ring A, whereas in gutingimycin N1 is above ring B and
O6 above ring A. The orientation of the sugars is almost
identical in both structures since they are held in place by
the same internal hydrogen bonds.
Figure 4. Simpliﬁed view of the DNA–trioxacarcin duplex with residue
names.
Figure 5. Space-ﬁlling view of the DNA–trioxacarcin duplex.
Trioxacarcin is shown in red (oxygen atoms) and light orange (carbon
atoms); the DNA is shown in light gray except for the phosphorus atoms
that are shown in black and the two residues containing the ﬂipped-out
thymines in green. On the bottom is the minor groove enclosing the
4-sugar, on the bottom the major groove containing the 13-sugar (left
side) and the two 16-methoxy groups (right-side). On the extreme upper
left-side, the terminal A(101) can be seen.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3511One trioxacarcin is involved in stacking interactions
with G(106) and A(2) (Figure 7A), the other with G(6)
and A(102). Residues T(108) and T(8) interact slightly
with the antibiotics but C(3) and C(103) do not. In the
case of daunomycin or nogalamycin the long axis of the
aglycone is nearly perpendicular to that of the base pairs
(6,7), but this is not the case for trioxacarcin, which is
constrained by the alkylation site. The aromatic rings A
and B of the trioxacarcins lie below the atoms N9, N3
and C10 of residues G(106) and G(6). The long axis of
the trioxacarcin aglycone is nearly parallel to that of the
alkylated guanine (Figure 7A) and runs close to the sugar-
phosphate backbone of this guanine. This orientation
brings the 10-methoxy groups of the trioxacarcins approx-
imately into the positions where the deoxyriboses of
residues T(107) and T(7) would lie if they were not
ﬂipped out. The ﬂipped-out thymines are positioned near
the 6-methyl groups of the trioxacarcins, the distance
between C2 of T(7) and 6-methyl of trioxacarcin(9) is
3.3A ˚ [3.6A ˚ for the corresponding atoms of T(107) and
trioxacarcin(109)].
Distortion of theDNA
The following analysis is based on standard nomenclature
of nucleic acid structure parameters (20). The base pairs of
Table 2. Backbone and glycosyl torsion angles
Angle, degrees
Residue ab g d e z w
A2 (next to intercalation) 282 176 60 155 254 280 209
A102 308 180 50 155 251 270 224
C3 (next to intercalation) 288 170 46 150 206 192 276
C103 287 157 52 147 218 188 274
C4 308 149 53 133 168 265 240
C104 298 139 56 134 183 238 242
G5 307 191 47 151 180 262 262
G105 311 181 48 149 181 268 259
G6 (next to intercalation) 293 183 51 144 238 264 273
G106 303 185 46 141 233 267 270
T7 (ﬂipped-out) 302 159 61 147 251 82 252
T107 281 184 69 161 254 74 258
T8 (next to intercalation) 276 172 51 143 – – 232
T108 236 184 81 130 – – 221
B-DNA (range) 270–330 130–200 20–80 70–180 160–270 150–300 200–300
B-DNA (mean) 298 176 (I) 48 128 (I) 184 (I) 265 (I) 258 (A/G)
146 (II) 144 (II) 246 (II) 174 (II) 241 (T/C)
271 (II)
Torsion angles are deﬁned as a:O 3
 -P-O5
 -C5
 , b: P-O5
 -C5
 -C4
 , g:O 5
 -C5
 -C4
 -C3
 , d:C 5
 -C4
 -C3
 -O3
 , e:C 4
 -C3
 -O3
 -P, z:C 3
 -O3
 -P-O5
 ,
w(Purines): O4
 -C1
 -N9-C4, w(Pyrimidines): O4
 -C1
 -N1-C2. For the mean values BI and BII conformations are distinguished, in the case of the
glycosyl torsion angle w also purines and pyrimidines for the BI conformation.
Figure 6. Stereoview of the DNA–trioxacarcin duplex. Base pair G(105)-C(4) is at the top, followed by base pair G(106)-C(3). Trioxacarcin A is
bound to G(106) and intercalates on its 30-side between base pair G(106)-C(3) and base pair T(108)-A(2), which is at the bottom. The carbon atoms
of the trioxacarcin are shown in light orange. The ﬂipped-out thymine is visible behind the trioxacarcin on the left. The red ball represents a water
molecule. Hydrogen bonds are indicated with dashed lines.
3512 Nucleic Acids Research, 2008, Vol. 36, No. 10the DNA–trioxacarcin duplex are distorted in several
diﬀerent ways. At the intercalation site they are not
planar; T(108)-A(2) is buckled by 98 and G(106)-C(3)
by –108 [T(8)-A(102) by –68 and G(6)-C(103) by 138].
This eﬀect is well known for intercalators and explained
by the need to maximize van der Waals contacts. The
helical twist angles from base pair T(108)-A(2) to base pair
A(102)-T(8) are 488,3 5 8,4 0 8,3 7 8 and 458; for B-DNA 378
is typical (20). Noncovalent intercalators such as dauno-
mycin or nogalamycin usually unwind DNA (reducing
these angles), whereas the intercalation of trioxacarcin
combined with the ﬂipping-out of a base in one of the two
strands leads to an increased helical twist and an opening
of the base pair (rotation of the bases relative to each
other in the plane of the base-pair) for T(108)-A(2) of 108
[88 for T(8)-A(102)] towards the major groove. The angle
between base pairs T(108)-A(2) and G(106)-C(3) (tilt) is
–128 and opens towards the strand with the ﬂipped-out
thymine T(107) [corresponding values for T(8)-A(102)/
G(6)-C(103)], also visible in Figure 6. Another distortion
induced by the trioxacarcin is a displacement along the
long axis of base pairs T(108)-A(2) and G(106)-C(3) (slide)
by 2.0A ˚ [2.2A ˚ for T(8)-A(102)/G(6)-C(103)], also visible
in Figure 7A. All these distortions are within the ranges
observed for both complexed and uncomplexed double-
stranded DNA structures.
Comparison with relatedDNA–antibiotic complexes
Structures of anthracyclines intercalated in DNA without
the formation of covalent bonds invariably show the drug
intercalated at the 50-side of a guanine, usually between C
and G or T and G. NMR studies of hedamycin–DNA
(9,21,22), altromycin–DNA (10) and psorospermin–DNA
(11) complexes, in which a covalent bond is formed by
nucleophilic attack of the guanine N7 on an epoxide as in
trioxacarcin, showed a similar intercalation site to that
observed for the anthracyclines, namely on the 50-side of
the alkylated guanine, without a ﬂipped-out nucleobase.
The crystal structure of trioxacarcin bound to d(AACC
GGTT) reported here reveals a quite diﬀerent intercala-
tion on the 30-side of guanine combined with a ﬂipped-out
thymine on the same side. This result is consistent with
sequence selectivity studies (4) that report a preferred
adduct formation with 50-AATTTGTAATT or 50-AATT
AGTAATT compared to 50-AATTTGAAATT or 50-AAT
TAGAAATT, showing that only a variation on the 30-side
of the alkylated guanine inﬂuences drug binding. In view
of the evidence from the crystal structure that A(102) and
A(2) pair with the thymine after the ﬂipped-out thymine,
we predict that trioxacarcin A should react preferentially
with the DNA sequence 50-GTT. In contrast, in the plura-
mycin and related complexes it is always the base on
the 50-side of the alkylated guanine that inﬂuences the
sequence speciﬁcity, consistent with the observed inter-
calation site.
Since trioxacarcin A does not react with a guanine
positioned at the 30-terminus of a DNA-oligonucleotide
(4), it appears that docking of the antibiotic, guided by
the hydrogen bonds discussed above and the location of
the bulky sugars in the minor and major grooves, with
preliminary noncovalent binding to the DNA-helix is a
prerequisite for the reaction of the trioxacarcin A with a
guanine base. The detailed structure of this noncovalent
complex before guanine attack is not yet known. It has to
be taken into account that trioxacarcin A would have
to thread into the DNA backbone, either by transient
melting or by unwinding of the helix (7,23).
The ﬂipping-out of bases plays an important role in
certain DNA–protein interactions; for example in the
Figure 7. (A) View down the DNA helix axis. The carbon atoms of the upper base pair G(106)-C(3) are drawn in green, the ones of the lower base
pair T(108)-A(2) in turquoise. The trioxacarcin is positioned between the two base pairs, with its carbon atoms colored in light orange. The carbon
atoms of the ﬂipped-out base T(107) are drawn in gray. (B) The small-molecule crystal structure of gutingimycin crystallized without DNA (5).
The carbon atoms of the guanine base are drawn in green.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3513DNA repair enzyme uracil-DNA glycosylase (UDG) the
discrimination between uracil and thymine is initiated by
thermally induced opening of TA and UA base pairs (24).
Base-pair dynamics may also be connected with the
sequence selectivity of trioxacarcin A. An unresolved
question is how streptomycetes protect their own DNA
from the drug.
This study has revealed a unique structure for a DNA–
drug complex that combines intercalation, alkylation and
base ﬂip-out. It provides insight into the mechanism of
the formation of gutingimycin with the abstraction of a
guanine base from DNA and adds to our understanding
of DNA manipulation by antibiotics.
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